Why do you waste so much energy on crickets, I looked at the Insider activity, it looks promising. Even the institutional transactions look good. I see a good chance of a pop up in the near future due to the fact that this is a biofarma but not sure how near. Good luck and happy Holidays to both Longs and Shorts.
First, we all have to "thank" Pucci for screwing us all. Getting a good compensation, he has no incentives to do anything useful for the company and its shareholders.
My new 2013 year wishes:
- Get good results in Ph2 trials in mCRC, prostate, breast, mKRAS NSCLC as well in Marquee and Attention readouts
- ARQL being bought out in 2H 2013 for $30+ (just over $1.7B). This is a very low price for a company with a promising drug in multiple cancer settings. But with incompetent bureaucrat, no-English speaking Pucci, it is difficult to expect much.